Results 1 to 10 of about 2,458,624 (375)

Factors contributing to the expansion of medication for opioid use disorder (MOUD) within the New Hampshire Department of Corrections (NHDOC) [PDF]

Health & Justice
Introduction Expanding access to medication for opioid use disorder (MOUD) to people involved in the carceral system is a priority for the New Hampshire Department of Corrections (NHDOC), where more than 40% of residents have an opioid use disorder (OUD).
Nancy Clayman, Pracha Eamranond, Helen Hanks, Michael Mitcheff, Lisa RappaMannion, Diane York, Paula Mattis, Heidi Guinen, Alex Carp, Laura Olson, Kathleen Bell, Lydia Shahi, Elizabeth Saunders, Joshua Lee, Lisa Marsch   +14 more
doaj   +2 more sources

Baseline Characteristics and Postdischarge Outcomes by Medication for Opioid Use Disorder Status Among Women with Polysubstance Use in Residential Treatment [PDF]

Women's Health Reports, 2023
Background: Within residential treatment, medication for opioid use disorder (MOUD) is rarely offered, so little is known about group differences by MOUD status.
Anna Beth Parlier-Ahmad, Sydney Kelpin, Caitlin E. Martin, Dace S. Svikis   +3 more
doaj   +2 more sources

Prevalence and predictors of medication for opioid use disorder among reproductive-aged women [PDF]

Drug and Alcohol Dependence Reports
Background: Women of reproductive age would benefit from treatment of opioid use disorder (OUD) prior to pregnancy to improve maternal and infant outcomes.
Jennifer K. Bello, Nathaniel A. Dell, Aaron M. Laxton, Mary Conte, Lynn Chen   +4 more
doaj   +2 more sources

A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence [PDF]

Contemporary Clinical Trials Communications, 2022
Background: There is an unmet need for non-medication approaches to illicit opioid discontinuation and relapse prevention. The NET (NeuroElectric Therapy) Device is a non-invasive, battery-operated, portable, re-useable device designed to deliver ...
Mark K. Greenwald, Samiran Ghosh, Joe R. Winston   +2 more
doaj   +3 more sources

The Lived Experience of Medication for Opioid Use Disorder: Qualitative Metasynthesis. [PDF]

J Addict Nurs, 2023
Abstract Purpose of the Study Buprenorphine and methadone, when used as maintenance therapy in opioid use disorder (OUD), can significantly reduce the risk of death after an opioid overdose. Despite the many benefits, medication for OUD (MOUD) remains controversial and underutilized.
Techau A, Gamm E, Roberts M, Garcia L.
europepmc   +3 more sources

ADHD: prevalence and effect on opioid use disorder treatment outcome in a French sample of patients receiving medication for opioid use disorder—the influence of impulsivity as a mediating factor [PDF]

Harm Reduction Journal
Background Opioid use disorder (OUD) poses a global health challenge, and despite medications for opioid use disorder (MOUD) and psychosocial interventions, relapse remains a significant concern.
Auxane Beslot, Marie Grall-Bronnec, Marianne Balem, Benoit Schreck, Edouard-Jules Laforgue, Caroline Victorri-Vigneau, Morgane Guillou-Landreat, Juliette Leboucher, OPAL-Group, Gaëlle Challet-Bouju, Clémence Cabelguen   +10 more
doaj   +2 more sources

Examining changes in pain interference via pandemic-induced isolation among patients receiving medication for opioid use disorder: a secondary data analysis [PDF]

BMC Public Health
Background Early in the pandemic, the United States population experienced a sharp rise in the prevalence rates of opioid use, social isolation, and pain interference.
Tessa Frohe, Tim Janssen, Bryan R. Garner, Sara J. Becker   +3 more
doaj   +2 more sources

Medication Treatment of Opioid Use Disorder [PDF]

Biological Psychiatry, 2020
Opioid use disorder (OUD) is a chronic, relapsing condition, often associated with legal, interpersonal, and employment problems. Medications demonstrated to be effective for OUD are methadone (a full opioid agonist), buprenorphine (a partial agonist), and naltrexone (an opioid antagonist).
James Bell, John Strang
openaire   +5 more sources

Prescribers’ satisfaction with delivering medications for opioid use disorder [PDF]

Substance Abuse Treatment, Prevention, and Policy, 2021
Abstract Background Expanding access to medications for opioid use disorder (MOUD), such as buprenorphine and extended release (XR) naltrexone, is critical to addressing the US opioid epidemic, but little is known about prescriber satisfaction with delivering these two types of MOUD.
Knudsen, Hannah K, Brown, Randy, Jacobson, Nora, Horst, Julie, Kim, Jee-Seon, Kim, Hanna, Madden, Lynn M, Haram, Eric, Molfenter, Todd   +8 more
openaire   +6 more sources

Medications Development for Treatment of Opioid Use Disorder [PDF]

Cold Spring Harbor Perspectives in Medicine, 2020
This review describes methods for preclinical evaluation of candidate medications to treat opioid use disorder (OUD). The review is founded on the propositions that (1) drug self-administration procedures provide the most direct method for assessment of medication effectiveness, (2) procedures that assess choice between opioid and nondrug reinforcers ...
E. Andrew Townsend, S. Stevens Negus, Matthew L. Banks   +2 more
openaire   +2 more sources